Table 3.

Recommendations regarding general management of cancer patients with CRV.

Population	Intention	Intervention	SoR	QoE	Reference
IS, infected persons, Contact persons	Infection control—prevent transmission	Hand hygiene	A	IIt	[49], [116]
IS, Infected persons, Contact persons	Infection control—prevent transmission	Face mask	B	IIt	[49], [116]
Infected persons	Infection control—prevent outbreak	Contact isolation	A	III	[117]
allo-SCT and evidence of CRV	Prevent disease, improve survival	Delay conditioning	A	II	[17]
All other chemotherapy and CRV	Prevent disease, improve survival	Delay chemotherapy if possible	C	III	[61]
allo-SCT and LRTI due to adenovirus	Prevent disease, shorten duration	Reduce immunosuppression	A	II	[36], [62]
allo-SCT and LRTI due to CRV	Prevent disease, shorten duration	Reduce immunosuppression	A	IIt	[36], [62]
allo-SCT and URTI	Prevent disease, shorten duration	Reduce immunosuppression	C	III
IS with evidence of CRV	Reduce morbidity	Steroids >2 mg/kg	D	III	[10]
IS with evidence of RSV	Prevent LRTI, improve survival	IVIG	B	III	[30], [82]
IS with evidence of influenza, PIV, hMPV	prevent LRTI, improve survival	IVIG	C	III	[118], [119], [92], [69]

SoR, strength of recommendation; QoE, quality of evidence; IS, immunosuppressed cancer patients; URTI, upper respiratory tract infection; LRTI, lower respiratory tract infection; CRV, community acquired respiratory virus; IVIG intravenous immunoglobulins; allo-SCT, allogeneic stem cell transplantation; RSV, respiratory syncytial virus; PIV, parainfluenza virus; hMPV, human metapneumovirus.